Evidence Hub

A dose-response and duration of action assessment of a combined preparation of fenoterol and ipratropium bromide (Duovent)

Packe GE, Archer PS, Cayton RM

Postgraduate medical journal, 1984

20 participants

Abstract

The dose-response relationships of a combination of the selective beta adrenergic agonist, fenoterol, and the synthetic anticholinergic drug, ipratropium bromide, were studied. In an open cross-over assessment, 20 patients with evidence of reversible airways obstruction inhaled 2, 4, 6 or 8 puffs from a metered dose inhaler, containing 100 micrograms fenoterol and 40 micrograms ipratropium bromide per puff, administered according to a randomization schedule, on four non-consecutive days. Before, and at intervals up to eight hours after inhalation FEV1, FVC, pulse and blood pressure were measured. Immediate and prolonged bronchodilatation followed each dose. The overall analysis of the FEV1, and FVC showed little difference between 2, 4 and 6 puffs. The highest dose, 8 puffs, was more effective, but associated with an increased incidence of side effects.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free